My Cart

Human VEGF165 Protein, premium grade

  • GMP version GMP-VE5H23 is now available for seamless transition.
Customer Reviews
Cat. No. / Size
Price
Qty
Premium grade lyophilized
VE5-H4210-20ug
$270.00
VE5-H4210-50ug
$395.00
VE5-H4210-1mg (500ug X 2)
$2845.00
GMP lyophilized
GMP-VE5H23-50ug
$570.00
GMP-VE5H23-1mg (50ug X 20)
$4325.00
GMP-VE5H23-10mg (50ug X 200)
$30275.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Features and Advantages

    1. Seamless Transition from Preclinical to Clinical: Same cell clone, process, and QC as GMP products.
    2. Enhanced Production Standards: AOF raw materials, pharma-grade excipients, Grade B+A (ISO 5) environment.
    3. Comprehensive Quality Control: Additional strict testing for process impurities, sterility, and mycoplasma.
    4. Cost-Effective Solution: GMP-comparable quality at an economical price for early development.
    5. Risk Mitigation: Enhanced safety through rigorous impurity control and comprehensive testing.
  • Synonym

    RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF

  • Source

    Human VEGF165, premium grade (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).

    Predicted N-terminus: Ala 27

    It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
    GMP-VE5H23 is the GMP version of this VE5-H4210. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stage to later clinical phases.

    Request for sequence
  • Molecular Characterization

    VEGF165 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries no "tag".

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Host Cell Protein

    <0.5 ng/µg of protein tested by ELISA.

  • Host Cell DNA

    <0.02 ng/μg of protein tested by qPCR.

  • Sterility

    Negative

  • Mycoplasma

    Negative

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process
  • Quality Description

    ACRO's Research-grade products are suitable for a wide range of cell culture applications, particularly for research use in academic institutions. These products are sterilized by filtration, followed by lyophilization where applicable. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. Biological activity is calibrated against WHO/NIBSC standards when available.
    ACRO's Premium-grade (Pre-GMP) products are characterized by their high quality and enhanced safety profiles, making them ideal for early-stage discovery and manufacturing processes in cell therapy companies. A key advantage is their seamless transition to corresponding GMP-grade versions. Biological activity is calibrated against WHO/NIBSC standards when available. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. In addition, rigorous testing is conducted to ensure the absence of mycoplasma, HCD, and HCP, thereby guaranteeing product safety.

Customers Also Viewed

Performance Data

  • SDS-PAGE

    VEGF165 SDS-PAGE

    Human VEGF165, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    VEGF165 SEC-MALS

    The purity of Human VEGF165, premium grade (Cat. No. VE5-H4210) is more than 95% and the molecular weight of this protein is around 42-60 kDa verified by SEC-MALS.

    Report
  • Bioactivity-CELL BASE

     VEGF165 CELL

    Human VEGF165, premium grade (Cat. No. VE5-H4210) stimulates 293-NFAT/Luc-VEGFR2 cells. The specific activity of Human VEGF165, premium grade is > 8.00 x 10^5 IU/mg, which is calibrated against human vascular endothelial growth factor 165 WHO International Standard (NIBSC code: 02/286) (QC tested).

    Protocol
  •  VEGF165 CELL

    Inhibition assay shows that the proliferation effect of Human VEGF165, premium grade (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).

    Protocol
  •  VEGF165 CELL

    Response to human VEGF165 protein (Fold).
    The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat. No. VE5-H4210). The max induction fold was approximately 70 (Routinely tested).

    Protocol
  • Bioactivity-ELISA

     VEGF165 ELISA

    Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 0.1 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 4-31 ng/mL (QC tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (Routinely tested).

    Protocol
  •  VEGF165 ELISA

    Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     VEGF165 SPR

    Anti-VEGFA Antibody, Human IgG1 captured on Protein A Chip can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 0.103 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     VEGF165 BLI

    Loaded bind Anti-VEGFA Antibody, Human IgG1 on AHC2 Biosensor, can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 53.8 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  VEGF165 BLI

    Loaded bind Human NRP1, Fc Tag (Cat. No. NR1-H5252) on Protein A Biosensor, can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 17.3 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  • Bioactivity-Stability

     VEGF165 STABILITY

    Cell-based assay demonstrates batch-to-batch consistency between Acro's GMP and PG VEGF165.

Customer Reviews
Writing Reviews

Background

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Recent Advances

 
Drug Development Progress
  • English Name:

    Vascular endothelial growth factor A

  • Category:

  • Approved Drugs:

    54 Details

  • Drugs in Clinical Trials:

    61 Details

  • Highest Development Stage:

    Approved

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland